Last update 08 May 2025

SWISS BIOPHARMA MED GmbH

Private Company

Overview

Basic Info

Introduction
Swixx BioPharma was founded to fully replace biopharma, OTC and medical device multinationals’ subsidiaries or business units in those countries, or therapeutic areas of CEE and beyond, that the multinational biopharma chooses not to enter, or to exit.

Tags

Skin and Musculoskeletal Diseases
Other Diseases
Monoclonal antibody

Disease domain score
A glimpse into the focused therapeutic areas
no Data
No Data
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Top 5 Drug TypeCount
Monoclonal antibody1
Top 5 TargetCount
CD47 x TNF x TNF-α1

Related

1
Drugs associated with SWISS BIOPHARMA MED GmbH
Monoclonal antibody (Mab) sB24M(SWISS BIOPHARMA)
Target
CD47 x TNF x TNF-α
Mechanism
CD47 inhibitors [+2]
Active Org.
SWISS BIOPHARMA MED GmbH
Originator Org.
SWISS BIOPHARMA MED GmbH
Active Indication
Pyoderma Gangrenosum
Inactive Indication-
Drug Highest PhaseEarly Phase 1
First Approval Ctry. / Loc.-
First Approval Date-
1
Clinical Trials associated with SWISS BIOPHARMA MED GmbH
NCT04895566
/ CompletedEarly Phase 1
Phase 0/1 Topical Application of the Monoclonal Antibody (Mab) sB24M in Patients With Severe Pyoderma
100 Clinical Results associated with SWISS BIOPHARMA MED GmbH
Login to view more data
0 Patents (Medical) associated with SWISS BIOPHARMA MED GmbH
Login to view more data
100 Deals associated with SWISS BIOPHARMA MED GmbH
Login to view more data
100 Translational Medicine associated with SWISS BIOPHARMA MED GmbH
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 08 May 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Phase 1 Clinical
1
Login to view more data

Current Projects

Drug(Targets)IndicationsGlobal Highest Phase
Monoclonal antibody (Mab) sB24M(SWISS BIOPHARMA)
 ( CD47 x TNF x TNF-α )		Pyoderma Gangrenosum
More
Phase 1 Clinical
Login to view more data

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free